Beyond the Standard Panel: Five Longevity Biomarkers Worth Asking For

Standard screening catches disease. A small set of additional biomarkers can catch the trajectory toward disease, years earlier. The previous article on this topic made the case that standard, evidence-backed screening — blood pressure, colonoscopy, mammography, lipids, glucose — comes first, and that’s still true. But once those basics are reliably in place, a handful of additional markers add real, well-supported value for anyone thinking seriously about healthspan rather than just disease detection.

The goal is trajectory, not just diagnosis

A standard panel is built to catch disease once it’s present: diabetes once glucose is high enough, heart disease once symptoms appear. The markers below are different — they describe a trajectory, often years before a standard test would flag anything abnormal. That lead time is exactly what makes them useful for a longevity-focused approach, where the goal is intervening on the slope of decline, not waiting for the threshold to be crossed.

The five worth discussing

• ApoB — a direct count of atherogenic particles, a more accurate predictor of cardiovascular risk than standard LDL cholesterol alone, and increasingly the preferred target for lipid-lowering therapy.
• hs-CRP (high-sensitivity C-reactive protein) — a simple, inexpensive marker of systemic inflammation. A level under 1.0 mg/L is a reasonable target; persistently elevated levels warrant investigating the underlying driver — sleep, visceral fat, or chronic stress.
• HbA1c — a three-month average of blood glucose that reveals metabolic drift well before a fasting glucose test would flag prediabetes, since fasting glucose can look normal even as underlying insulin resistance builds.
• DEXA scan — measures bone density and body composition, including muscle mass, directly. This catches sarcopenia and osteopenia years before a fracture or a change on a standard exam would reveal either.
• VO2 max — maximal oxygen uptake during exercise, the single strongest predictor of all-cause mortality available to a clinician, and one of the most modifiable numbers on this list at any age.

The woman whose labs looked fine for a decade

A woman in her mid-forties had unremarkable annual labs for years — normal fasting glucose, normal cholesterol on the standard panel, nothing flagged. An expanded panel told a more complete story: HbA1c in the upper-normal range, ApoB elevated despite an unremarkable LDL cholesterol, and hs-CRP consistently above 3.0 mg/L. None of these individually crossed a diagnostic threshold, but together they described a clear metabolic and vascular trajectory heading in the wrong direction.

Addressing the pattern — primarily through reducing visceral fat and improving sleep — brought all three markers into a healthier range within a year, years before any of them would have crossed into standard “disease” territory on their own.

Why this matters

None of these five tests require exotic access or extreme cost, and most can be requested at a routine physical or ordered through standard labs. The point isn’t to chase every emerging biomarker on the market — many direct-to-consumer panels promise far more than the evidence supports. It’s to add this specific, well-validated handful once the fundamentals are already covered, so trajectory becomes visible years before a diagnosis would otherwise be the first clue.

Adapted from Built to Last: The Longevity Blueprint by Charan Shikh, MD.